Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparative Study of Intragastric Balloon and Pharmacotherapy for Non-Morbid Obesity

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2006 by Chinese University of Hong Kong.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT00355979
First received: July 24, 2006
Last updated: October 17, 2006
Last verified: July 2006

July 24, 2006
October 17, 2006
March 2006
Not Provided
Body weight loss in terms of % of body weight and BMI loss at 6-month and 1 year.
Same as current
Complete list of historical versions of study NCT00355979 on ClinicalTrials.gov Archive Site
Regain of weight after treatment, complications and compliance of treatment, change of satiety level and calorie intake during and after treatment, quality of life, change in hormonal profile and patient's satisfaction
Same as current
Not Provided
Not Provided
 
Comparative Study of Intragastric Balloon and Pharmacotherapy for Non-Morbid Obesity
Randomized Trial of Intragastric Balloon and Pharmacotherapy for Non-Morbid Obesity

To evaluate and compare the effectiveness of intragastric balloon and Sibutramine (Reductil®) in the treating of non-morbid obese in a randomized controlled manner

Obesity is a chronic devastating disease and is becoming a major health and socioeconomic issue worldwide. Obesity significantly exacerbates many other chronic illnesses and increases mortality and morbidities of patients.1-2 Although the situation in Asians is less apparent and critical than in Caucasians, the problem is emerging rapidly. In Hong Kong, there are approximately 29% of adults classified as obese according WHO Asian criteria 3 and there is an increasing demand for obesity treatment in Asia-Pacific region.4 The first practical aim of treating obesity nowadays should focus on a sustained body weight loss of 10-15% to alleviate obesity-related illnesses such as hypertension, diabetes and obstructive sleep apnoea.

Intragastric balloon (IGB) was initially developed from observing the effects naturally caused by bezoars and the first documentation in human use was reported in 1982.5 However, earlier balloon designs were plagued by high balloon failure rates and serious complications.6-8 Since then, balloon design has undergone several major modifications in terms of material, shape and filling substances. The newer design of balloon (Bioenterics® Intragastric Balloon (BIB®) system) was introduced in 1999 9 and has undergone extensive evaluation recently in Europe with promising results.10-11 It is placed inside the stomach endoscopically for a maximum of 180 days to decrease stomach capacity and gastric emptying. It facilitates patient’s compliance to the restricted diet prescribed and together with increasing level of physical activities, most reports have shown moderate body weight loss of 15 % or more.10--12 More importantly, the newer design balloon (BIB) is more reliable and predictable. The reported premature balloon rupture and serious complication is rare if it is removed within the recommended period and followed up carefully by a dedicated obesity team in a multidisciplinary approach.10-12 Sibutramine (Reductil®) is a serotonin and noradrenaline reuptake inhibitor and is one of the FDA approved weight reduction pharmacotherapy. Its central action on neurotransmitters causes an enhancement of satiety (fullness) after eating. In addition, it causes sympathetically mediated thermogenesis, which prevent the reduction in basal metabolic rate (BMR) normally seen in individual on restricted diet and thereby effectively increases resting energy consumption and promotes weight loss. A combination of sibutramine and lifestyle modification program has been shown up to 10 % of body weight loss while intragastric balloon and sibutramine are the two most commonly used non-surgical method for weight reduction. There is lack of randomized controlled trial in comparing these two methods in the treatment of obesity. Since these two types of therapy are most efficient in non-morbid obese patients, we are designing a trial to compare the effect of the two different weight reduction therapies in this group of patients in a double-blind manner.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Obesity
Device: intragastric balloon
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
March 2008
Not Provided

Inclusion Criteria:

  1. Age 18-60
  2. BMI 27-35
  3. Agree to undergo invasive weight reduction therapy and intensive follow-up
  4. No history of weight reduction for >5% of BW for the past 6 months

Exclusion Criteria:

  1. Coronary heart disease
  2. Un-controlled hypertension (160/90 mmHg)
  3. unstable cardiovascular disease
  4. unstable cerebrovascular disease
  5. Renal disease
  6. Liver disease

9) Diabetes Mellitus 10) Eating disorder 11) Psychiatric illness 12) Pregnant or breast feeding

Both
18 Years to 60 Years
Yes
Contact: Wilfred LM Mui, FRCS 26322627 wilfredmui@hotmail.com
China
 
NCT00355979
CRE-2006.084
Not Provided
Not Provided
Chinese University of Hong Kong
Not Provided
Principal Investigator: Wilfred LM Mui, FRCS The Chinese University of Hong Kong, Hong Kong ,China
Chinese University of Hong Kong
July 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP